{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:58:58Z","timestamp":1792432738239,"version":"4.5.0"},"reference-count":271,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007639","name":"Maire Taposen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007639","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014809","name":"Technology Agency of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"DOI":"10.3389\/fchem.2020.00276","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T05:30:21Z","timestamp":1587447021000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":89,"title":["Transcription and Translation Inhibitors in Cancer Treatment"],"prefix":"10.3389","volume":"8","author":[{"given":"Nihay","family":"Laham-Karam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaspar P.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Poso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piia","family":"Kokkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1159\/000356571","article-title":"TAS-106: preclinical, clinical and beyond","volume":"85","author":"Abdelrahim","year":"2013","journal-title":"Oncology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4155\/fsoa-2018-0115","article-title":"Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy","volume":"5","author":"Alqahtani","year":"2019","journal-title":"Future Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.chembiol.2014.09.001","article-title":"Small-molecule inhibitors of protein-protein interactions: progressing toward the reality","volume":"21","author":"Arkin","year":"2014","journal-title":"Chem. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3390\/cancers3033279","article-title":"Assessment of the evolution of cancer treatment therapies","volume":"3","author":"Arruebo","year":"2011","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug. Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jmb.2019.10.018","article-title":"Local chromatin motion and transcription","volume":"432","author":"Babokhov","year":"2020","journal-title":"J. Mol. Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1182\/blood-2004-05-1699","article-title":"Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP","volume":"105","author":"Balakrishnan","year":"2005","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12154-008-0003-5","article-title":"Rapamycin and mTOR kinase inhibitors","volume":"1","author":"Ballou","year":"2008","journal-title":"J. Chem. Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.pan.2015.05.472","article-title":"Minnelide, a novel drug for pancreatic and liver cancer","volume":"15","author":"Banerjee","year":"2015","journal-title":"Pancreatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/esmoopen-2017-000246","article-title":"Ribociclib: a valuable addition to treatment options in breast cancer?","volume":"2","author":"Bartsch","year":"2017","journal-title":"ESMO Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Invest New Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd4505","article-title":"Targeting the translation machinery in cancer","volume":"14","author":"Bhat","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.3109\/10428194.2013.783911","article-title":"Emerging drug profile: cyclin-dependent kinase inhibitors","volume":"54","author":"Blachly","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/leu.2011.109","article-title":"Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol","volume":"25","author":"Blum","year":"2011","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/neuonc\/noq142","article-title":"Targeted therapy for high-grade glioma with the TGF-\u03b22 inhibitor trabedersen: results of a randomized and controlled phase IIb study","volume":"13","author":"Bogdahn","year":"2011","journal-title":"Neuro Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.celrep.2014.08.025","article-title":"Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition","volume":"8","author":"Bolden","year":"2014","journal-title":"Cell Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1172\/JCI34753","article-title":"Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model","volume":"118","author":"Bordeleau","year":"2008","journal-title":"J. Clin. Invest."},{"key":"B19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.gene.2019.06.023","article-title":"Gene promoter methylation and cancer: an umbrella review","volume":"710","author":"Bouras","year":"2019","journal-title":"Gene"},{"key":"B20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0007-1536(57)80033-3","article-title":"Wortmannin, an antibiotic produced by Penicillium wortmanni","volume":"40","author":"Brian","year":"1957","journal-title":"Trans. Br. Mycol. Soc."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28294","article-title":"8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia","author":"Buettner","year":"2019","journal-title":"J. Cell. Physiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","article-title":"Targeting transcription factors in cancer \u2014 from undruggable to reality","volume":"19","author":"Bushweller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ccr.2012.05.019","article-title":"Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53","volume":"22","author":"Bywater","year":"2012","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrg3355","article-title":"RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond","volume":"14","author":"Castel","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e5223","DOI":"10.1371\/journal.pone.0005223","article-title":"Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol","volume":"4","author":"Cencic","year":"2009","journal-title":"PLoS ONE"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and degree of CDK drug interactions predicts clinical performance","volume":"15","author":"Chen","year":"","journal-title":"Mol. Cancer Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1093\/nar\/gkv228","article-title":"A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications","volume":"43","author":"Chen","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12885-015-1988-0","article-title":"Silvestrol induces early autophagy and apoptosis in human melanoma cells","volume":"16","author":"Chen","year":"","journal-title":"BMC Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0095-0","article-title":"Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials","volume":"4","author":"Cheng","year":"2019","journal-title":"Signal Trans. Targeted Therap."},{"key":"B32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14304\/surya.jpr.v4n7.5","article-title":"RNA therapeutics: RNAi and antisense mechanisms and clinical applications","volume":"4","author":"Chery","year":"2016","journal-title":"Postdoc J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Choo","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/0092-8674(92)90643-q","article-title":"Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases","volume":"69","author":"Chung","year":"1992","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/0005-2787(74)90182-8","article-title":"Animal DNA-dependent RNA polymerases 11. Mechanism of the inhibition of RNA polymerases B by amatoxins","volume":"353","author":"Cochet-Meilhac","year":"1974","journal-title":"Biochim. Biophys. Acta"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.18632\/oncotarget.2020","article-title":"DNA intercalator BMH-21 inhibits RNA polymerase I independent of DNA damage response","volume":"5","author":"Colis","year":"2014","journal-title":"Oncotarget"},{"key":"B37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ajh.23408","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors","volume":"88","author":"Cortes","year":"2013","journal-title":"Am. J. Hematol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-3233(04)67001-X","article-title":"Structure and Function of RNA Polymerase II","volume-title":"Advances in Protein Chemistry Proteins in Eukaryotic Transcription","author":"Cramer","year":"2004"},{"key":"B40","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.cell.2019.09.018","article-title":"Eukaryotic transcription turns 50","volume":"179","author":"Cramer","year":"2019","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1056\/NEJMra072367","article-title":"Oncogenes and cancer","volume":"358","author":"Croce","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular mechanisms of antisense oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Therap."},{"key":"B43","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nrc906","article-title":"Transcription factors as targets for cancer therapy","volume":"2","author":"Darnell","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fphar.2017.00177","article-title":"Fludarabine Inhibits KV1.3 Currents in Human B Lymphocytes","volume":"8","author":"de la Cruz","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1038\/onc.2010.154","article-title":"Therapeutic CDK4\/6 inhibition in breast cancer: key mechanisms of response and failure","volume":"29","author":"Dean","year":"2010","journal-title":"Oncogene"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5622","DOI":"10.1182\/blood-2010-05-285866","article-title":"8-Aminoadenosine inhibits Akt\/mTOR and Erk signaling in mantle cell lymphoma","volume":"116","author":"Dennison","year":"2010","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.1021\/jm400487c","article-title":"Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development","volume":"56","author":"Ding","year":"2013","journal-title":"J. Med. Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-10-1728","article-title":"Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth","volume":"71","author":"Drygin","year":"2011","journal-title":"Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/21655979.2016.1207011","article-title":"Bioengineered non-coding RNA agent (BERA) in action","volume":"7","author":"Duan","year":"2016","journal-title":"Bioengineered"},{"key":"B51","doi-asserted-by":"publisher","first-page":"942","DOI":"10.2174\/1389450120666181126123538","article-title":"Saccharomyces cerevisiae (Baker's Yeast) as an interfering RNA expression and delivery system","volume":"20","author":"Duman-Scheel","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"B52","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000499534","article-title":"Management of adverse events due to cyclin-dependent kinase 4\/6 inhibitors","volume":"14","author":"Ettl","year":"2019","journal-title":"BRC"},{"key":"B53","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nature13896","article-title":"mTORC1-mediated translational elongation limits intestinal tumour initiation and growth","volume":"517","author":"Faller","year":"2015","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ccell.2017.01.014","article-title":"A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma","volume":"31","author":"Fan","year":"2017","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ccr.2006.03.029","article-title":"A dual PI3 kinase\/mTOR inhibitor reveals emergent efficacy in glioma","volume":"9","author":"Fan","year":"2006","journal-title":"Cancer Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Feldman","year":"2009","journal-title":"PLoS Biol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1158\/1078-0432.CCR-05-2505","article-title":"Chemotherapy and targeted therapy combinations in advanced melanoma","volume":"12","author":"Flaherty","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"11449","DOI":"10.1021\/bi901479b","article-title":"Characterization of a ras mutant with identical GDP- and GTP-bound structures","volume":"48","author":"Ford","year":"2009","journal-title":"Biochemistry"},{"key":"B63","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1182\/blood.V130.Suppl_1.4048.4048","article-title":"Preliminary results from an ongoing phase 1\/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with advanced malignancies","volume":"130","author":"Forero-Torres","year":"2017","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"eaap8307","DOI":"10.1126\/scitranslmed.aap8307","article-title":"Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis","volume":"10","author":"Frankowski","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1432-1033.1977.tb11256.x","article-title":"Inhibition of translation in eukaryotic systems by harringtonine","volume":"72","author":"Fresno","year":"1977","journal-title":"Eur. J. Biochem."},{"key":"B66","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1158\/1535-7163.MCT-09-0767","article-title":"8-Amino-adenosine inhibits multiple mechanisms of transcription","volume":"9","author":"Frey","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"B67","unstructured":"A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors16891696 FridayB. LassereY. MeyersC. A. MitaA. AbbruzzeseJ. L. ThomasM. B. 22593447Anticancer Res.322012"},{"key":"B68","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.18632\/oncotarget.3551","article-title":"Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery","volume":"6","author":"Fu","year":"2015","journal-title":"Oncotarget"},{"key":"B69","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrm.2016.143","article-title":"Functions of bromodomain-containing proteins and their roles in homeostasis and cancer","volume":"18","author":"Fujisawa","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1016\/j.bmcl.2016.08.010","article-title":"Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument","volume":"26","author":"Furet","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B71","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1517\/13543776.2013.789861","article-title":"Cyclin-dependent kinase inhibitors closer to market launch?","volume":"23","author":"Galons","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"B72","unstructured":"8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells54745479 GandhiV. AyresM. HalgrenR. G. KrettN. L. NewmanR. A. RosenS. T. 11454694Cancer Res.612001"},{"key":"B73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00003088-200241020-00002","article-title":"Cellular and clinical pharmacology of fludarabine","volume":"41","author":"Gandhi","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1158\/1078-0432.CCR-13-1283","article-title":"Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia","volume":"20","author":"Gandhi","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.1158\/1538-7445.AM2018-5789","article-title":"Abstract 5789: discovery of clinical candidate BMS-986158, an oral BET inhibitor, for the treatment of cancer","volume":"78","author":"Gavai","year":"2018","journal-title":"Cancer Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"B77","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/mus.26001","article-title":"Making sense of antisense oligonucleotides: a narrative review","volume":"57","author":"Goyal","year":"2018","journal-title":"Muscle Nerve"},{"key":"B78","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","article-title":"A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity","volume":"4","author":"Grabiner","year":"2014","journal-title":"Cancer Discov."},{"key":"B79","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s10637-018-0578-9","article-title":"A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer","volume":"36","author":"Graham","year":"2018","journal-title":"Invest New Drugs"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1158\/1535-7163.MCT-15-0365","article-title":"AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules","volume":"14","author":"Guichard","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1208\/s12248-011-9276-7","article-title":"Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1\/P-glycoprotein overexpression in acute lymphoblastic leukemia cells","author":"Gupta","year":"2011","journal-title":"AAPS J."},{"key":"B82","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jmb.2009.04.005","article-title":"U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome","volume":"389","author":"G\u00fcrel","year":"2009","journal-title":"J. Mol. Biol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1021\/ml300110s","article-title":"Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for cancer therapeutics","volume":"3","author":"Haddach","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"B85","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 Provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"key":"B86","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s10637-010-9535-y","article-title":"Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies","volume":"30","author":"Hammond-Thelin","year":"2012","journal-title":"Invest. New Drugs"},{"key":"B87","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3389\/fgene.2019.00478","article-title":"The potential for microRNA therapeutics and clinical research","volume":"10","author":"Hanna","year":"2019","journal-title":"Front. Genet."},{"key":"B88","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/wrna.17","article-title":"No-go decay: a quality control mechanism for RNA in translation","volume":"1","author":"Harigaya","year":"2010","journal-title":"WIREs RNA"},{"key":"B89","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1124\/jpet.118.247775","article-title":"Bioengineered noncoding RNAs selectively change cellular miRNome profiles for cancer therapy","volume":"365","author":"Ho","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1021\/acschembio.9b00367","article-title":"Structural basis for inhibition of human primase by arabinofuranosyl nucleoside analogues fludarabine and vidarabine","volume":"14","author":"Holzer","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016"},{"key":"B93","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature10912","article-title":"The translational landscape of mTOR signalling steers cancer initiation and metastasis","volume":"485","author":"Hsieh","year":"2012","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-19-0119","article-title":"Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7","volume":"79","author":"Hu","year":"2019","journal-title":"Cancer Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nbt.2537","article-title":"Efficient and specific gene knockdown by small interfering RNAs produced in bacteria","volume":"31","author":"Huang","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"B97","first-page":"511","article-title":"Harringtonine, an inhibitor of initiation of protein biosynthesis","volume":"11","author":"Huang","year":"1975","journal-title":"Mol. Pharmacol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/sj.leu.2401845","article-title":"Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine","volume":"14","author":"Huang","year":"2000","journal-title":"Leukemia"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1021\/jo040120f","article-title":"Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris","volume":"69","author":"Hwang","year":"2004","journal-title":"J. Org. Chem."},{"key":"B100","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-1-61779-430-8_10","article-title":"Evaluation of mTOR-regulated mRNA translation","volume":"821","author":"Iadevaia","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/cas.13942","article-title":"Roles of EphA1\/A2 and ephrin-A1 in cancer","volume":"110","author":"Ieguchi","year":"2019","journal-title":"Cancer Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"key":"B103","doi-asserted-by":"publisher","first-page":"30742","DOI":"10.18632\/oncotarget.16372","article-title":"Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models","volume":"8","author":"Jian","year":"2017","journal-title":"Oncotarget"},{"key":"B104","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.omtn.2019.01.007","article-title":"Bioengineered Let-7c inhibits orthotopic hepatocellular carcinoma and improves overall survival with minimal immunogenicity","volume":"14","author":"Jilek","year":"2019","journal-title":"Mol. Therap. Nucleic Acids"},{"key":"B105","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nature07755","article-title":"A three-dimensional view of the molecular machinery of RNA interference","volume":"457","author":"Jinek","year":"2009","journal-title":"Nature"},{"key":"B106","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0021-9258(18)54022-9","article-title":"Kinetic and structural analysis of the Mg(2+)-binding site of the guanine nucleotide-binding protein p21H-ras","volume":"268","author":"John","year":"1993","journal-title":"J. Biol. Chem."},{"key":"B107","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1042\/EBC20170056","article-title":"Exploiting cancer vulnerabilities: mTOR, autophagy, and homeostatic imbalance","volume":"61","author":"Johnson","year":"2017","journal-title":"Essays Biochem."},{"key":"B108","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B109","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Junwei","year":"2014","journal-title":"Mol. Cell"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1236566","DOI":"10.1126\/science.1236566","article-title":"mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin","volume":"341","author":"Kang","year":"2013","journal-title":"Science"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.82105","article-title":"Antisense oligonucleotides, A novel developing targeting therapy","author":"Karaki","year":"2019","journal-title":"Antisense Therapy"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1002\/bit.26740","article-title":"Milligram scale production of potent recombinant small interfering RNAs in Escherichia coli","volume":"115","author":"Kaur","year":"2018","journal-title":"Biotechnol. Bioeng."},{"key":"B113","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1517\/13543784.9.12.2903","article-title":"Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status","volume":"9","author":"Kelland","year":"2000","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B114","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bbrc.2016.06.021","article-title":"RVX-297- a novel BD2 selective inhibitor of BET bromodomains","volume":"477","author":"Kharenko","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-18-1455","article-title":"First-in-Human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study","volume":"9","author":"Khot","year":"2019","journal-title":"Cancer Discov."},{"key":"B116","doi-asserted-by":"publisher","first-page":"20723","DOI":"10.1073\/pnas.1314307110","article-title":"Mutant KRAS is a druggable target for pancreatic cancer. Proc. Natl. Acad. Sci","volume":"110","author":"Khvalevsky","year":"2013","journal-title":"U.S.A."},{"key":"B117","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.addr.2016.06.011","article-title":"Recent progress in development of siRNA delivery vehicles for cancer therapy","volume":"104","author":"Kim","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B119","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41556-018-0205-1","article-title":"mTOR as a central hub of nutrient signalling and cell growth","volume":"21","author":"Kim","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/1097-0215(20000520)89:3<251::AID-IJC7>3.0.CO;2-5","article-title":"Expression of TGF-\u03b2 isoforms, TGF-\u03b2 receptors, and SMAD molecules at different stages of human glioma","volume":"89","author":"Kjellman","year":"2000","journal-title":"Int. J. Cancer"},{"key":"B121","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nature06765","article-title":"Sequence- and target-independent angiogenesis suppression by siRNA via TLR3","volume":"452","author":"Kleinman","year":"2008","journal-title":"Nature"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e76136","DOI":"10.1371\/journal.pone.0076136","article-title":"Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer","volume":"8","author":"Kogure","year":"2013","journal-title":"PLoS ONE"},{"key":"B123","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.tibs.2005.03.011","article-title":"Mediator and the mechanism of transcriptional activation","volume":"30","author":"Kornberg","year":"2005","journal-title":"Trends Biochem. Sci."},{"key":"B124","doi-asserted-by":"publisher","first-page":"21741","DOI":"10.18632\/oncotarget.15566","article-title":"Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K\/mTOR inhibitor with preferential response in PI3K\/PTEN mutant glioma","volume":"8","author":"Koul","year":"2017","journal-title":"Oncotarget"},{"key":"B125","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/msb.2013.47","article-title":"Protein synthesis rate is the predominant regulator of protein expression during differentiation","volume":"9","author":"Kristensen","year":"2013","journal-title":"Mol. Syst. Biol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.sbi.2019.10.007","article-title":"Transcription through the nucleosome","volume":"61","author":"Kujirai","year":"2019","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/358070a0","article-title":"Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase","volume":"358","author":"Kuo","year":"1992","journal-title":"Nature"},{"key":"B128","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1089\/ars.2017.7248","article-title":"Activating the chromatin by noncoding RNAs","volume":"29","author":"Laham-Karam","year":"2018","journal-title":"Antioxid. Redox Signal."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.molcel.2019.12.029","article-title":"Directed RNase H cleavage of nascent transcripts causes transcription termination","volume":"77","author":"Lai","year":"2020","journal-title":"Mol. Cell"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3390\/molecules24081516","article-title":"Advances in the understanding of skin cancer: ultraviolet radiation, mutations, and antisense oligonucleotides as anticancer drugs","volume":"24","author":"Laikova","year":"2019","journal-title":"Molecules"},{"key":"B131","doi-asserted-by":"publisher","first-page":"6910","DOI":"10.1158\/0008-5472.CAN-05-0530","article-title":"Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery","volume":"65","author":"Landen","year":"2005","journal-title":"Cancer Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.molcel.2019.12.011","article-title":"Antisense-mediated transcript knockdown triggers premature transcription termination","volume":"77","author":"Lee","year":"2020","journal-title":"Mol. Cell"},{"key":"B133","doi-asserted-by":"publisher","first-page":"104508","DOI":"10.1016\/j.phrs.2019.104508","article-title":"Non-canonical transcriptional consequences of BET inhibition in cancer","volume":"150","author":"Letson","year":"2019","journal-title":"Pharmacol. Res."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/j.biocel.2013.05.030","article-title":"Targeting long non-coding RNAs in cancers: progress and prospects","volume":"45","author":"Li","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","article-title":"Rapamycin: one drug, many effects","volume":"19","author":"Li","year":"2014","journal-title":"Cell Metab."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1124\/dmd.115.064493","article-title":"Chimeric MicroRNA-1291 biosynthesized efficiently in Escherichia coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity","volume":"43","author":"Li","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"B137","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.1093\/nar\/gkz500","article-title":"mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway","volume":"47","author":"Liang","year":"","journal-title":"Nucleic Acids Res."},{"key":"B138","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13046-019-1232-x","article-title":"Inhibition of RNA polymerase III transcription by Triptolide attenuates colorectal tumorigenesis","volume":"38","author":"Liang","year":"","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B139","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1126\/science.170.3956.447","article-title":"Specific inhibition of nuclear RNA polymerase II by alpha-amanitin","volume":"170","author":"Lindell","year":"1970","journal-title":"Science"},{"key":"B140","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41416-019-0499-1","article-title":"Direct Ras G12C inhibitors: crossing the rubicon","volume":"121","author":"Lindsay","year":"2019","journal-title":"Br. J Cancer"},{"key":"B141","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1093\/nar\/gkz214","article-title":"Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines","volume":"47","author":"Linnane","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B142","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1158\/0008-5472.CAN-12-1702","article-title":"Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR","volume":"73","author":"Liu","year":"2013","journal-title":"Cancer Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1089\/dna.1989.8.595","article-title":"Drug Inhibitors of RNA Polymerase II Transcription","volume":"8","author":"Logan","year":"1989","journal-title":"DNA"},{"key":"B144","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-015-0194-5","article-title":"Palbociclib: a first-in-class CDK4\/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer","volume":"8","author":"Lu","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1182\/blood-2008-09-175430","article-title":"The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo","volume":"113","author":"Lucas","year":"2009","journal-title":"Blood"},{"key":"B146","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","article-title":"Toxicity of cationic lipids and cationic polymers in gene delivery","volume":"114","author":"Lv","year":"2006","journal-title":"J. Control. Release"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.biochi.2007.05.007","article-title":"Overlapping pathways dictate termination of RNA polymerase II transcription","volume":"89","author":"Lykke-Andersen","year":"2007","journal-title":"Biochimie"},{"key":"B148","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1002\/jcph.957","article-title":"RNA therapeutics in oncology: advances, challenges, and future directions","volume":"57","author":"MacLeod","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1080\/10428194.2017.1283030","article-title":"Homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia","volume":"58","author":"Maiti","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B150","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/35106065","article-title":"To cycle or not to cycle: a critical decision in cancer","volume":"1","author":"Malumbres","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"B151","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"B152","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cell.2004.08.002","article-title":"Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6","volume":"118","author":"Malumbres","year":"2004","journal-title":"Cell"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00018-007-7474-3","article-title":"Protein factors in pre-mRNA 3'-end processing","volume":"65","author":"Mandel","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"B154","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1158\/0008-5472.CAN-12-1006","article-title":"Natural product triptolide mediates cancer cell death by triggering CDK7-dependent degradation of RNA polymerase II","volume":"72","author":"Manzo","year":"2012","journal-title":"Cancer Res."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/cncr.20975","article-title":"Phase I\/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib","volume":"103","author":"Marin","year":"2005","journal-title":"Cancer"},{"key":"B156","doi-asserted-by":"publisher","first-page":"a019323","DOI":"10.1101\/cshperspect.a019323","article-title":"RNAi and heterochromatin assembly","volume":"7","author":"Martienssen","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","article-title":"ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer","volume":"1","author":"Miller","year":"2011","journal-title":"Cancer Discov."},{"key":"B158","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/jnci\/djs140","article-title":"Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma","volume":"104","author":"Moldenhauer","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"B159","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s10637-013-9964-5","article-title":"Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors","volume":"32","author":"Naing","year":"2014","journal-title":"Invest N. Drugs"},{"key":"B160","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nbt.3427","article-title":"Antisense oligonucleotide\u2013directed inhibition of nonsense-mediated mRNA decay","volume":"34","author":"Nomakuchi","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1200\/jco.2011.29.15_suppl.2513","article-title":"Phase I\/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma","volume":"29","author":"Oettle","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/labinvest.2015.46","article-title":"Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F","volume":"95","author":"Oliveira","year":"2015","journal-title":"Lab. Invest."},{"key":"B163","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"B164","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","article-title":"Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design","volume":"15","author":"Ostrem","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"B165","doi-asserted-by":"publisher","first-page":"e14527","DOI":"10.1200\/JCO.2018.36.15_suppl.e14527","article-title":"HDP-101: preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma","volume":"36","author":"Pahl","year":"","journal-title":"J. Clin. Oncol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ddtec.2018.08.005","article-title":"Amanitins and their development as a payload for antibody-drug conjugates","volume":"30","author":"Pahl","year":"","journal-title":"Drug Discov. Today Technol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.cell.2015.06.017","article-title":"The utilization of extracellular proteins as nutrients is suppressed by mTORC1","volume":"162","author":"Palm","year":"2015","journal-title":"Cell"},{"key":"B168","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1039\/c4np00006d","article-title":"Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species","volume":"31","author":"Pan","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"B169","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.csbj.2019.12.004","article-title":"The current understanding of KRAS protein structure and dynamics","volume":"18","author":"Pantsar","year":"2020","journal-title":"Comp. Struct. Biotechnol. J."},{"key":"B170","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.sbi.2019.10.001","article-title":"Recent insights into the structure of TFIID, its assembly, and its binding to core promoter","volume":"61","author":"Patel","year":"2020","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nrc2966","article-title":"RNA interference in the clinic: challenges and future directions","volume":"11","author":"Pecot","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"B172","doi-asserted-by":"publisher","first-page":"e12996","DOI":"10.1371\/journal.pone.0012996","article-title":"Identification of Novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents","volume":"5","author":"Peltonen","year":"2010","journal-title":"PLoS ONE"},{"key":"B173","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2013.12.009","article-title":"A targeting modality for destruction of RNA polymerase I that possesses anticancer activity","volume":"25","author":"Peltonen","year":"2014","journal-title":"Cancer Cell"},{"key":"B174","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.trecan.2017.05.003","article-title":"RNA-binding proteins in cancer: old players and new actors","volume":"3","author":"Pereira","year":"","journal-title":"Trends Cancer"},{"key":"B175","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1080\/21655979.2017.1284710","article-title":"New insights for therapeutic recombinant human miRNAs heterologous production: Rhodovolum sulfidophilum vs Escherichia coli","volume":"8","author":"Pereira","year":"","journal-title":"Bioengineered"},{"key":"B176","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/15592294.2016.1265710","article-title":"Bromodomain inhibitors and cancer therapy: from structures to applications","volume":"12","author":"P\u00e9rez-Salvia","year":"2016","journal-title":"Epigenetics"},{"key":"B177","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1158\/1078-0432.CCR-17-3645","article-title":"Target-based screening against eIF4A1 reveals the marine natural product elatol as a novel inhibitor of translation initiation with in vivo anti-tumor activity","volume":"24","author":"Peters","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3324\/haematol.2012.067140","article-title":"A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation","volume":"97","author":"Pidala","year":"2012","journal-title":"Haematologica"},{"key":"B179","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature14229","article-title":"Architecture of the RNA polymerase II-Mediator core initiation complex","volume":"518","author":"Plaschka","year":"2015","journal-title":"Nature"},{"key":"B180","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-pathol-012414-040312","article-title":"Driver and passenger mutations in cancer","volume":"10","author":"Pon","year":"2015","journal-title":"Annu. Rev. Pathol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.omtn.2020.01.027","article-title":"An antisense oligonucleotide leads to suppressed transcription of Hdac2 and long-term memory enhancement","volume":"19","author":"Poplawski","year":"2020","journal-title":"Mol. Ther. Nucleic. Acids"},{"key":"B182","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","article-title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.1380182","article-title":"Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase","volume":"257","author":"Price","year":"1992","journal-title":"Science"},{"key":"B184","doi-asserted-by":"publisher","first-page":"aad9926","DOI":"10.1126\/science.aad9926","article-title":"Transcriptional termination in mammals: stopping the RNA polymerase II juggernaut","volume":"352","author":"Proudfoot","year":"2016","journal-title":"Science"},{"key":"B185","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1177\/0192623316645860","article-title":"Preclinical safety evaluation in rats of a polymeric matrix containing an siRNA drug used as a local and prolonged delivery system for pancreatic cancer therapy","volume":"44","author":"Ramot","year":"2016","journal-title":"Toxicol Pathol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.4161\/auto.29119","article-title":"Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma","volume":"10","author":"Rangwala","year":"2014","journal-title":"Autophagy"},{"key":"B187","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1053\/j.gastro.2010.01.007","article-title":"Proliferative suppression by CDK4\/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells","volume":"138","author":"Rivadeneira","year":"2010","journal-title":"Gastroenterology"},{"key":"B188","doi-asserted-by":"publisher","first-page":"e5428","DOI":"10.1371\/journal.pone.0005428","article-title":"Altering chemosensitivity by modulating translation elongation","volume":"4","author":"Robert","year":"2009","journal-title":"PLoS ONE"},{"key":"B189","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13148-019-0675-4","article-title":"Epigenetics in cancer therapy and nanomedicine","volume":"11","author":"Roberti","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"B190","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1021\/jm201263k","article-title":"Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies","volume":"55","author":"Rodrigo","year":"2012","journal-title":"J. Med. Chem."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/cells8101225","article-title":"Transcriptional regulation of energy metabolism in cancer cells","volume":"8","author":"Rodr\u00edguez-Enr\u00edquez","year":"2019","journal-title":"Cells"},{"key":"B192","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nature17963","article-title":"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor","volume":"534","author":"Rodrik-Outmezguine","year":"2016","journal-title":"Nature"},{"key":"B193","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0968-0004(96)10050-5","article-title":"The role of general initiation factors in transcription by RNA polymerase II","volume":"21","author":"Roeder","year":"1996","journal-title":"Trends Biochem. Sci."},{"key":"B194","doi-asserted-by":"publisher","first-page":"eaal5253","DOI":"10.1126\/scitranslmed.aal5253","article-title":"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS","volume":"9","author":"Ross","year":"2017","journal-title":"Sci. Trans. Med."},{"key":"B195","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1586\/17474086.2016.1151351","article-title":"Omacetaxine mepesuccinate for chronic myeloid leukemia","volume":"9","author":"Rosshandler","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"e00070-18","DOI":"10.1128\/MCB.00070-18","article-title":"Signaling pathways involved in the regulation of mRNA translation","volume":"38","author":"Roux","year":"2018","journal-title":"Mol. Cell. Biol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"21549","DOI":"10.1074\/jbc.271.35.21549","article-title":"Amanitin greatly reduces the rate of transcription by RNA polymerase II ternary complexes but fails to inhibit some transcript cleavage modes","volume":"271","author":"Rudd","year":"1996","journal-title":"J. Biol. Chem."},{"key":"B198","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1074\/jbc.270.2.815","article-title":"Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells","volume":"270","author":"Sabers","year":"1995","journal-title":"J. Biol. Chem."},{"key":"B199","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1182\/blood-2019-124391","article-title":"Specific targeting of KRAS using a novel high-affinity KRAS antisense oligonucleotide in multiple myeloma","volume":"134","author":"Sacco","year":"2019","journal-title":"Blood"},{"key":"B200","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3892\/ijo.2018.4661","article-title":"From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review)","volume":"54","author":"Schirrmacher","year":"2018","journal-title":"Int. J. Oncol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41580-018-0011-4","article-title":"Roadblocks and resolutions in eukaryotic translation","volume":"19","author":"Schuller","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/s0041-1345(03)00211-2","article-title":"Sirolimus: its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant. Proc."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1515\/znb-1969-1211","article-title":"Alpha-amanitin, a specific inhibitor of transcription by mammalian RNA-polymerase","volume":"24","author":"Seifart","year":"1969","journal-title":"Z. Naturforsch B"},{"key":"B204","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1023\/a:1006353008903","article-title":"Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials","volume":"17","author":"Senderowicz","year":"1999","journal-title":"Invest New Drugs"},{"key":"B205","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B206","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.molcel.2018.10.016","article-title":"Arginine citrullination at the C-terminal domain controls RNA polymerase II transcription","volume":"73","author":"Sharma","year":"2019","journal-title":"Mol. Cell"},{"key":"B207","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1021\/acsmedchemlett.8b00167","article-title":"Discovery of an orally bioavailable dual PI3K\/mTOR inhibitor based on sulfonyl-substituted morpholinopyrimidines","volume":"9","author":"Shen","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"B208","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/j.1349-7006.2002.tb01325.x","article-title":"Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2","volume":"93","author":"Shimamoto","year":"2002","journal-title":"Jpn. J. Cancer Res."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3389\/fimmu.2019.01246","article-title":"Bone Marrow Transplantation 1957-2019","volume":"10","author":"Simpson","year":"2019","journal-title":"Front. Immunol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/978-1-4939-8651-4_26","article-title":"Pre-mRNA splicing modulation by antisense oligonucleotides","volume":"1828","author":"Singh","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/cancers10110396","article-title":"Prolonged idasanutlin (RG7388) treatment leads to the generation of p53-mutated cells","volume":"10","author":"Skalniak","year":"2018","journal-title":"Cancers"},{"key":"B212","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2019.10.017","article-title":"The role of non-coding RNAs in oncology","volume":"179","author":"Slack","year":"2019","journal-title":"Cell"},{"key":"B213","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbagrm.2012.08.008","article-title":"Transcription-associated histone modifications and cryptic transcription","volume":"1829","author":"Smolle","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"B215","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/biom9110668","article-title":"FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management","volume":"9","author":"Solassol","year":"2019","journal-title":"Biomolecules"},{"key":"B216","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","article-title":"Regulation of translation initiation in eukaryotes: mechanisms and biological targets","volume":"136","author":"Sonenberg","year":"2009","journal-title":"Cell"},{"key":"B217","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Therap."},{"key":"B218","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1200\/jco.2004.22.90140.4106","article-title":"TGF-\u03b22 suppression by the antisense oligonucleotide AP 12009 as treatment for pancreatic cancer: preclinical efficacy data","volume":"22","author":"Stauder","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-approved oligonucleotide therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol. Ther."},{"key":"B220","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.3390\/cancers3044170","article-title":"Transcription inhibition as a therapeutic target for cancer","volume":"3","author":"Stellrecht","year":"2011","journal-title":"Cancers"},{"key":"B221","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/bjh.14859","article-title":"Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy","volume":"179","author":"Stellrecht","year":"2017","journal-title":"Br. J. Haematol."},{"key":"B222","first-page":"144","article-title":"[Comparative clinical study of rheumatoid arthritis treated by triptolide and an ethyl acetate extract of Tripterygium wilfordii]","volume":"10","author":"Su","year":"1990","journal-title":"Zhong Xi Yi Jie He Za Zhi"},{"key":"B223","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"Tabernero","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/cas.13965","article-title":"Development of miRNA-based therapeutic approaches for cancer patients","volume":"110","author":"Takahashi","year":"2019","journal-title":"Cancer Sci."},{"key":"B225","doi-asserted-by":"publisher","first-page":"115235","DOI":"10.1016\/j.bmc.2019.115235","article-title":"Small molecules targeting HIF-1\u03b1 pathway for cancer therapy in recent years","volume":"28","author":"Tang","year":"2019","journal-title":"Bioorg. Med. Chem"},{"key":"B226","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1530\/ERC-10-0262","article-title":"Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer","volume":"18","author":"Thangavel","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"B227","doi-asserted-by":"publisher","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Thoreen","year":"2009","journal-title":"J. Biol. Chem."},{"key":"B228","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/ijms20030755","article-title":"mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy","volume":"20","author":"Tian","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B229","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nchembio.522","article-title":"XPB, a subunit of TFIIH, is a target of the natural product triptolide","volume":"7","author":"Titov","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"B230","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1021\/jm049354h","article-title":"Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6","volume":"48","author":"Toogood","year":"2005","journal-title":"J. Med. Chem."},{"key":"B231","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00928361","article-title":"Physiological concentrations of purines and pyrimidines","volume":"140","author":"Traut","year":"1994","journal-title":"Mol. Cell Biochem."},{"key":"B232","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/cam4.79","article-title":"Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer","volume":"2","author":"Tsao","year":"2013","journal-title":"Cancer Med."},{"key":"B233","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2018.10.038","article-title":"Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models","volume":"442","author":"Tu","year":"2019","journal-title":"Cancer Lett."},{"key":"B234","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B235","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/bs.acr.2017.06.002","article-title":"Cancer hallmarks and MicroRNAs: the therapeutic connection","volume":"135","author":"Van Roosbroeck","year":"2017","journal-title":"Adv. Cancer Res."},{"key":"B236","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1021\/jm049355","article-title":"Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4","volume":"48","author":"VanderWel","year":"2005","journal-title":"J. Med. Chem."},{"key":"B237","doi-asserted-by":"publisher","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"V\u00e9zina","year":"1975","journal-title":"J. Antibiot."},{"key":"B238","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1475-2867-14-18","article-title":"The basal transcription machinery as a target for cancer therapy","volume":"14","author":"Villica\u00f1a","year":"2014","journal-title":"Cancer Cell Int."},{"key":"B239","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/1535-7163.MCT-09-0549","article-title":"Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA","volume":"8","author":"Visp\u00e9","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"B240","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","article-title":"Insights into the regulation of protein abundance from proteomic and transcriptomic analyses","volume":"13","author":"Vogel","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"B241","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1158\/1535-7163.MCT-16-0541","article-title":"Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA)","volume":"16","author":"Wagner","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B242","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/13543776.2019.1640680","article-title":"A patent review of BRAF inhibitors: 2013-2018","volume":"29","author":"Wang","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"B243","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1124\/jpet.115.225631","article-title":"Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: high-yield expression and purification, and structural and functional characterization","volume":"354","author":"Wang","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B244","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3858\/emm.2009.41.10.078","article-title":"Triptolide downregulates Rac1 and the JAK\/STAT3 pathway and inhibits colitis-related colon cancer progression","volume":"41","author":"Wang","year":"2009","journal-title":"Exp. Mol. Med."},{"key":"B245","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1093\/nar\/gku184","article-title":"Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides","volume":"42","author":"Ward","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B246","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/nchembio.2210","article-title":"Potent and selective bivalent inhibitors of BET bromodomains","volume":"12","author":"Waring","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"B247","first-page":"609","article-title":"Part 5: regulation","volume-title":"Molecular Biology of the Gene","author":"Watson","year":"2013"},{"key":"B248","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.celrep.2018.03.066","article-title":"Small-molecule targeting of RNA polymerase I activates a conserved transcription elongation checkpoint","volume":"23","author":"Wei","year":"2018","journal-title":"Cell Rep."},{"key":"B249","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/138161211795049778","article-title":"Omacetaxine as an anticancer therapeutic: what is old is new again","volume":"17","author":"Wetzler","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"B250","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S1359-6446(05)03547-6","article-title":"First clinical data on RNAi","volume":"10","author":"Whelan","year":"2005","journal-title":"Drug Discov. Today"},{"key":"B251","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4615-1809-9_5","article-title":"Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells","volume":"1","author":"Wiederrecht","year":"1995","journal-title":"Prog. Cell Cycle Res."},{"key":"B252","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.drup.2012.01.008","article-title":"Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance","volume":"15","author":"Wilting","year":"2012","journal-title":"Drug Resist. Update"},{"key":"B253","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature13485","article-title":"RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer","volume":"513","author":"Wolfe","year":"2014","journal-title":"Nature"},{"key":"B254","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.12688\/f1000research.9207.1","article-title":"mTOR inhibitors in cancer therapy","volume":"5","author":"Xie","year":"2016","journal-title":"F1000Res"},{"key":"B255","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"key":"B256","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.3390\/ijms20174224","article-title":"Development and clinical trials of nucleic acid medicines for pancreatic cancer treatment","volume":"20","author":"Yamakawa","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B257","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3389\/fonc.2019.00953","article-title":"New horizons in KRAS-mutant lung cancer: dawn after darkness","volume":"9","author":"Yang","year":"2019","journal-title":"Front. Oncol."},{"key":"B258","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/cts.12624","article-title":"Targeting RNA: a transformative therapeutic strategy","volume":"12","author":"Yin","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"B259","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pharmthera.2018.11.011","article-title":"RNA therapy: are we using the right molecules?","volume":"196","author":"Yu","year":"2019","journal-title":"Pharmacol. Therap."},{"key":"B260","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1021\/acsmedchemlett.8b00002","article-title":"Discovery of pyridopyrimidinones as potent and orally active dual inhibitors of PI3K\/mTOR","volume":"9","author":"Yu","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"B261","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","article-title":"Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia","volume":"39","author":"Zeidner","year":"2015","journal-title":"Leuk. Res."},{"key":"B262","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13046-019-1059-5","article-title":"MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer","volume":"38","author":"Zhang","year":"","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B263","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/13543776.2019.1552261","article-title":"c-Met kinase inhibitors: an update patent review (2014-2017)","volume":"29","author":"Zhang","year":"","journal-title":"Exp. Opin. Ther. Pat."},{"key":"B264","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ijpharm.2018.06.026","article-title":"Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo","volume":"547","author":"Zhang","year":"2018","journal-title":"Int. J. Pharm."},{"key":"B265","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.2147\/OTT.S210128","article-title":"Dual PI3K\/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis","volume":"12","author":"Zhao","year":"2019","journal-title":"Oncol. Targets Ther."},{"key":"B266","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep26611","article-title":"Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest","volume":"6","author":"Zhao","year":"2016","journal-title":"Sci. Rep."},{"key":"B267","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bcp.2015.10.015","article-title":"Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth","volume":"98","author":"Zhao","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"B268","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13059-019-1870-5","article-title":"Epigenetic modifications of histones in cancer","volume":"20","author":"Zhao","year":"2019","journal-title":"Genome Biol."},{"key":"B269","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cbpa.2019.02.012","article-title":"Modulating protein-protein interaction networks in protein homeostasis","volume":"50","author":"Zhong","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B270","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B271","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd4685","article-title":"Clinical experiences with systemically administered siRNA-based therapeutics in cancer","volume":"14","author":"Zuckerman","year":"2015","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fchem.2020.00276\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T23:09:23Z","timestamp":1615331363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fchem.2020.00276\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":271,"alternative-id":["10.3389\/fchem.2020.00276"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2020.00276","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"article-number":"276"}}